Furthermore, there is a gap between guidelines and clinical practice, (7) as substantial numbers of patients continue to be treated with an oral anticoagulant and antiplatelet agent
. The use of an antiplatelet agent
after PCI reduces the risk of ischaemic or atherothrombotic events(8) but raises the risk of bleeding".
Aspirin is economically priced antiplatelet agent
which is extremely safe and effective.
First, patients received even one dosage of antiplatelet agent
within 90 days were enrolled in this study.
Aspirin inhibits platelet cyclooxygenase and thromboxane A2 and has been the most widely used antiplatelet agent
. Dipyridamole is an inhibitor of phosphodiesterase.
Looking at all patients taking warfarin (regardless of whether or not they were also taking an NSAID or antiplatelet agent
), PPI co-therapy reduced the risk of hospitalization for upper GI bleeding by 24% (adjusted hazard ratio [HR]=0.76; 95% confidence interval [CI], 0.63 to 0.91), which translates into 29 fewer hospitalizations per 10,000 person-years.
When a patient is on an anticoagulant or antiplatelet agent
, it takes longer for primary hemostasis to occur; subsequently bleeding time is prolonged.
It proposed a clinical response to Clopidogrel, an oral, thienopyridine-class antiplatelet agent
used to inhibit blood clots in coronary artery disease.
In this sub analysis for a new antiplatelet agent
, this combination therapy did not prove to be useful, on the contrary, it produced more harm.
Other combinations such as oral anticoagulation, and 1 antiplatelet agent
or DAPT alone were less commonly selected.
Ticagrelor: A Novel Reversible Oral Antiplatelet Agent
. Cardiol Rev.
In a prospective study with 1,358 patients presenting with acute coronary syndromes to the emergency department, with a 30-day follow-up, 5.4 % (n = 73) had stopped taking their oral antiplatelet agent
3 weeks before the acute episode, and the majority (64 %) had done so on the doctor's orders because of an upcoming elective procedure.
A large clinical trial (n=1358) involving hospitalized patients admitted with an acute coronary syndrome placed patients into three groups: those who had never taken an oral antiplatelet agent
[nonusers] (n=930), those with a history of prior use (n=355) and those who had recently discontinued use (n=73).